Influence of diffuse nontoxic goiter on placental insufficiency, course of gestation and childbirth

Main Article Content

O.S. Payenok
I.V. Pankiv
B.R. Hrytsyshyn
M.O. Kostiv


Background. There are significant disorders in the functioning of the mother-placenta-fetus system in women with thyroid pathology, especially in chronic iodine deficiency. This leads to complications of pregnancy, childbirth with a threat to the newborn’s health. The purpose of the study was to investigate the effect of potassium iodide in combination with sodium selenite and cytoflavin in women with diffuse nontoxic goiter for the correction of disorders in the mother-placenta-fetus during pregnancy. Materials and methods. To assess the state of pregnancies in the period from 2012 to 2017, 159 pregnant women and their newborns, who formed two groups, were examined. The first group consisted of 79 pregnant women with diffuse nontoxic goiter, who did not receive potassium iodide and other drugs for various reasons. The second group was formed by 80 women, who received potassium iodide (200 μg/day) in combination with sodium selenite and cytoflavin. Results. Chronic fetoplacental insufficiency is registered in 21.1 % of cases, with a significant difference in its incidence in two groups of women surveyed: 27.9 % in group I and 14.3 % in group II. The level of thyroid-stimulating hormone in children born from women in the first and second groups did not differ significantly and did not exceed the normal values (4.72 ± 1.22 mIU/l and 2.73 ± 1.01 mIU/l, respectively). The concentration of thyroid-stimulating hormone in the blood of infants of the second group was 42.2 % lower than in the newborns of the first group. Conclusions. The beneficial effect of taking potassium iodide in combination with sodium selenite and cytoflavin during gestation on the development of the fetus reveals itself by a statistically significant reduction in the incidence of intrauterine complications in group II compared with group I of the study: chronic fetoplacental insufficiency (14.3 and 27.9 %, respectively; p < 0.05) and chronic fetal hypotrophy (13.8 and 28.6 %, respectively, p < 0.05).

Article Details

How to Cite
Payenok, O., I. Pankiv, B. Hrytsyshyn, and M. Kostiv. “Influence of Diffuse Nontoxic Goiter on Placental Insufficiency, Course of Gestation and Childbirth”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 14, no. 2, May 2018, pp. 138-42, doi:10.22141/2224-0721.14.2.2018.130557.
Original Researches


Cignini P, Cafà EV, Giorlandino C, Capriglione S, Spata A, Dugo N. Thyroid physiology and common diseases in pregnancy: review of literature. J Prenat Med. 2012;6(4):64-71. PMID: 23272277.

Negro R, Mestman JH. Thyroid disease in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011 Dec;25(6):927-43. doi: 10.1016/j.beem.2011.07.010.

Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010 Oct;31(5):702-55. doi: 10.1210/er.2009-0041.

El Baba KA, Azar ST. Thyroid dysfunction in pregnancy. Int J Gen Med. 2012;5:227-30. doi: 10.2147/IJGM.S27009.

Gaberšček S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol. 2011 Sep;7(5):697-706; quiz 707. doi: 10.1586/eci.11.42.

Casey B, Leveno K. Thyroid disease in pregnancy. Obstet Gynecol. 2006;108(5):1283-1292. doi: 10.1097/01.AOG.0000244103.91597.c5.

Vaidya B, Anthony S, Bilous M, et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? J Clin Endocrinol Metab. 2007 Jan;92(1):203-7. doi: 10.1210/jc.2006-1748.

Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007 Aug;92(8 Suppl):S1-47. doi: 10.1210/jc.2007-0141.

Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev. 2010 Oct;31(5):702-55. doi: 10.1210/er.2009-0041.

Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab. 2010 Apr;95(4):1699-707. doi: 10.1210/jc.2009-2009.

Yassa L, Marqusee E, Fawcett R, Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010 Jul;95(7):3234-41. doi: 10.1210/jc.2010-0013.

Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol. 2008 Jul;112(1):85-92. doi: 10.1097/AOG.0b013e3181788dd7.

Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012 Feb 9;366(6):493-501. doi: 10.1056/NEJMoa1106104.

Glinoer D, Spencer CA. Serum TSH determinations in pregnancy: how, when and why? Nat Rev Endocrinol. 2010 Sep;6(9):526-9. doi: 10.1038/nrendo.2010.91.

Dosiou C, Sanders GD, Araki SS, Crapo LM.. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur J Endocrinol. 2008 Jun;158(6):841-51. doi: 10.1530/EJE-07-0882.

Most read articles by the same author(s)

1 2 3 4 > >>